An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients With Carcinoid Syndrome (CS)

被引:0
|
作者
Duchateau, Luc [1 ]
Lescrauwaet, Benedicte [2 ]
Blot, Koenraad [2 ]
Liyanage, Nilani [3 ]
Ray, David [4 ]
Lowenthal, Susan Pitman [3 ]
Braun, Stephan [3 ]
Mirakhur, Beloo [4 ]
机构
[1] Univ Ghent, Ghent, Belgium
[2] Xintera Ltd, Cambridge, England
[3] Ipsen Innovat, Basking Ridge, NJ USA
[4] Ipsen Biopharmaceut, Paris, France
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:338 / 338
页数:1
相关论文
共 50 条
  • [1] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
    Duchateau, L.
    Lescrauwaet, B.
    Blot, K.
    Liyanage, N.
    Ray, D.
    Lowenthal, S. P.
    Braun, S.
    Mirakhur, B.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 194 - 194
  • [2] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Gomez-Panzani, E.
    Vinik, A.
    Wolin, E.
    Audry, H.
    [J]. NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 271 - 271
  • [4] Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
    Fisher, G. A., Jr.
    Wolin, E.
    Kunz, P. L.
    Liyanage, N.
    Mirakhur, B.
    Lowenthal, S. Pitman
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S457 - S458
  • [7] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study
    Wolin, Edward M.
    Fisher, George A., Jr.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Mirakhur, Beloo
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S468 - S468
  • [9] Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT
    Wolin, E. M.
    Fisher, G. A.
    Kunz, P. L.
    Liyanage, N.
    Lowenthal, S. P.
    Mirakhur, B.
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Vinik, Aaron I.
    Wolin, Edward M.
    Liyanage, Nilani
    Gomez-Panzani, Edda
    Fisher, George A.
    [J]. ENDOCRINE PRACTICE, 2016, 22 (09) : 1068 - 1080